Stocks fell sharply on Thursday as U.S.-China trade worries persisted with more companies suspending business with Chinese telecom giant Huawei.Marketsread more
A Ministry of Commerce spokesperson does not single out any U.S. action, but it's been a tense couple of weeks for the trade war.World Politicsread more
The e-mail's optimistic tone helped Tesla shares turn positive for the first time in seven days.Technologyread more
In a four-page letter sent Thursday morning, Warren and Ocasio-Cortez asked Mnuchin a series of questions about his advisory role in former Sears CEO Eddie Lampert's...Politicsread more
"For them to say that they don't work with the Chinese government is false," Secretary of State Mike Pompeo tells CNBC.Politicsread more
Facebook has stopped paying commission to staff for selling political advertisements on its platform, The Wall Street Journal reported.Technologyread more
The yield on the 10-year Treasury note fell to its lowest level since 2017 as more traders grew confident in a longer U.S.-China conflict.Bondsread more
Prosecutors allege Stephen Calk, former president of Chicago-based Federal Savings Bank, loaned former Trump campaign chair Paul Manafort as much as $16 million in exchange...Politicsread more
At McDonald's annual shareholder meeting Thursday, executives said that the company is still monitoring plant-based meat substitutes.Restaurantsread more
Oil prices tumble as the market braces for a prolonged U.S.-China trade war and on signs the U.S. is willing to negotiate with Iran.Energy Commoditiesread more
U.S. manufacturer growth hit new lows in May, the latest sign that the economic slowdown accelerated amid the ongoing trade war.Economyread more
"Lowering the cost of prescription drugs is a shared common interest, and those conversations will continue," the person said, asking not to be identified because the discussions aren't public.
The official wouldn't say what the legislation might look like or when a bill might be introduced. Politico first reported the news.
High drug costs have become a rare bipartisan issue, with lawmakers on both sides of the aisle demanding something be done. President Donald Trump has made lowering prices one of his key issues ahead of the 2020 election. Democrats are also jockeying to prove they can lead reform.
Last month, top executives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi testified before the Senate Finance Committee about high prescription drug costs. Spending on prescription drugs in the U.S. increased to $333.4 billion in 2017, according to data from the Centers for Medicare and Medicaid Services.
Drug companies argue that price increases have been modest, and have instead pointed the blame at pharmacy benefit managers, sometimes called middlemen. They say that PBMs should pass the rebates negotiated with manufacturers along to patients. Drugmakers applauded the administration's pursuit to change the nation's rebate system.
White House Domestic Policy Council Director Joe Grogan and legislative director Shahira Knight are leading the talks for the Trump administration. Wendell Primus, Pelosi's health policy staffer, is leading the talks for the House Democrats.
"We've been having some staff-level discussions with the administration about lowering prescription drug prices, but they aren't negotiations," Pelosi spokesman Henry Connelly told CNBC.
"House Democrats promised the American people we'd take bold action to lower prescription drug prices, and that's what we're going to do," he added.
--CNBC's Ylan Mui contributed to this report.